VXN-319 is a semi-synthetic conjugate early-stage vaccine candidate.
VXN-319 is a carbohydrate-based vaccine.
Vaxxilon estimates it would provide protection against more than 80% of carbapenem resistant strains.
Vaxxilon synthesizes the carbohydrates that resemble the sugar coating which surrounds each bacterial cell.
The synthetic carbohydrates are then combined with other components to create conjugate vaccines similar to those that have been approved to prevent infections from bacteria such as Streptococcus pneumoniae and Haemophilus influenzae type B.